HRMY
NASDAQ
US
Harmony Biosciences Holdings, Inc. - Common Stock
$27.74
▼ $-0.22
(-0.79%)
Vol 524K
13
Quality Score
ok
Deep Check
2/5
ok
Rev ✓
NI ✓
>IPO ✗
Mkt Cap
$2.2B
P/E
11.6
ROE
24.9%
Margin
22.5%
D/E
20.18
Beta
0.86
52W
$26–$41
Wall Street Consensus
17 analysts · Apr 20263
Strong Buy
8
Buy
5
Hold
1
Sell
0
Strong Sell
64.7%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 50.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $0.91 | $0.38 | $-0.53 |
| Sep 2025 | $0.86 | $0.87 | +$0.01 |
| Jun 2025 | $0.77 | $0.68 | $-0.09 |
| Mar 2025 | $0.60 | $0.78 | +$0.18 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $201.3M | $184.7M | $200.5M | $239.5M | $243.8M |
| Net Income | — | $49.5M | $45.6M | $39.8M | $50.9M | $22.5M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | 26.3% | 26.3% | 26.3% | 26.3% | 24.9% | 24.9% |
| P/E (TTM) | 10.03 | 11.59 | 8.55 | 9.09 | 11.17 | 11.61 |
| Net Margin | 19.8% | 23.4% | 23.4% | 23.4% | 22.5% | 22.5% |
| Gross Margin | 81.0% | 78.3% | 78.3% | 78.3% | 77.7% | 77.7% |
| D/E Ratio | 22.26 | 22.26 | 22.26 | 22.26 | 20.18 | 20.18 |
| Current Ratio | 3.84 | 3.84 | 3.84 | 3.84 | 3.75 | 3.75 |
Key Ratios
ROA (TTM)
17.0%
P/S (TTM)
2.61
P/B
3.0
EPS (TTM)
$3.18
CF/Share
$2.87
Rev Growth 3Y
+32.8%
52W High
$40.93
52W Low
$25.52
$25.52
52-Week Range
$40.93
Financial Health
Free Cash Flow
$126.0M
Net Debt
-$588.8M
Cash
$752.5M
Total Debt
$163.7M
As of Dec 31, 2025
How does HRMY compare to Pharmaceuticals peers?
Peer group: Mid-cap Pharmaceuticals ($2B+) · 25 companies
HRMY valuation vs Pharmaceuticals peers
P/E ratio
11.6
▼
62%
below
peers
(30.7)
vs Peers
vs Industry
Undervalued
P/S ratio
2.6
▼
61%
below
peers
(6.7)
vs Peers
vs Industry
Undervalued
P/B ratio
3.0
▼
43%
below
peers
(5.2)
vs Peers
vs Industry
Pricier
Div yield
—
▼
0%
below
peers
(3.1%)
vs Peers
vs Industry
Low yield
HRMY profitability vs Pharmaceuticals peers
ROE
24.9%
▲
195%
above
peers
(-26.1%)
vs Peers
vs Industry
Top tier
Net margin
22.5%
▲
1650%
above
peers
(-1.5%)
vs Peers
vs Industry
Top tier
Gross margin
77.7%
▼
13%
below
peers
(88.9%)
vs Peers
vs Industry
Weak
ROA
17.0%
▲
280%
above
peers
(-9.5%)
vs Peers
vs Industry
Top tier
HRMY financial health vs Pharmaceuticals peers
D/E ratio
20.2
▼
26%
below
peers
(27.4)
vs Peers
vs Industry
Above avg
Current ratio
3.8
▲
8%
above
peers
(3.5)
vs Peers
vs Industry
In line
Beta
0.9
▲
45%
above
peers
(0.6)
vs Peers
vs Industry
More volatile
HRMY fundamentals radar
HRMY
Peer median
Industry
HRMY profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
HRMY vs peers: key metrics
Latest News
No related news yet